Hook & thesis
Community Healthcare Trust (CHCT) is a compact healthcare REIT trading at $18.33 with a market cap roughly $528 million and a headline dividend yield north of 10%. The company has increased its quarterly payout every quarter since its IPO and most recently declared a $0.48 quarterly dividend payable on 05/22/2026 (ex-dividend 05/11/2026), which annualizes to $1.92 per share. For income-seeking investors who can stomach episodic volatility and above-average leverage, CHCT is an attractive yield trade with upside to capital appreciation if FFO recovers and the market re-rates the stock closer to historical or peer multiples.
My actionable plan: initiate a long position at $18.30, protect with a stop loss at $16.00, and target $22.00 over a long-term horizon (180 trading days). This is a trade for investors focused on cash yield plus mid-single-digit capital gains if the company steadies operations and leasing continues to normalize.
What the business does and why investors should care
CHCT acquires and owns real estate leased to hospitals, doctors, healthcare systems and other healthcare service providers. The appeal of a healthcare-focused REIT is two-fold: long-term leases tied to essential services and portfolio cash flow that can be sticky even in economic downdrafts. CHCT is small — about 28.83 million shares outstanding and a float near 26.8 million — which increases stock-level volatility but also means a relatively concentrated opportunity set if management executes.
The market should care because CHCT marries (1) an above-market yield (annualized $1.92 per share) with (2) a portfolio profile that benefits from demographic tailwinds in healthcare. If management can stabilize FFO and control capital deployment, the dividend yield will look increasingly attractive relative to other fixed-income alternatives. Conversely, the balance sheet and recent cash flow volatility are real constraints that make the company a trade rather than a pure buy-and-forget income vehicle.
Hard numbers that matter
| Metric | Value |
|---|---|
| Current price | $18.33 |
| Market cap | $528.5M |
| Dividend (quarterly) | $0.48 (payable 05/22/2026) |
| Annualized dividend | $1.92 (yield ~10.25%) |
| Price / Book | ~1.24 |
| Price / Earnings | ~173 |
| Debt / Equity | 1.33 |
| Enterprise value | $1.080B |
| EV / EBITDA | ~14.42 |
| Free cash flow | -$58.16M |
| 52-week range | $13.23 - $19.13 |
Those line items show the dual nature of the investment: valuation (P/B ~1.24) does not look stretched, and the current price is only modestly below the 52-week high of $19.13 (07/17/2026). But earnings and cash flow measures are weak or negative — EPS is near $0.11 and free cash flow is a large negative item at about -$58M — which helps explain the high P/E and why dividend sustainability should be watched closely.
Recent operating context
The company has a history of raising dividends every quarter since its IPO, most recently increasing the quarterly payout to $0.48 on 04/30/2026 and paying on 05/22/2026. That streak is positive for investor confidence. However, CHCT reported a painful operating event: Q2 2025 FFO fell about 47% (reported 07/30/2025), driven by a tenant credit event and elevated severance costs. That episode is the primary reason for negative FCF and compresses near-term margin expansion.
Valuation framing
At roughly $528 million market cap and EV near $1.08 billion, CHCT occupies the lower end of publicly traded healthcare REITs in size. The price-to-book of ~1.24 implies that the market values CHCT close to its tangible equity base, which is reasonable for a company with a diversified healthcare portfolio and active acquisition strategy. EV/EBITDA at ~14.4 is not cheaply priced but not exuberant compared with mid-cap REITs that trade at double-digit multiples when growth prospects are intact. The combination of a high cash yield and a moderate P/B gives a valuation case: investors are being paid to wait for operational normalization.
This is not a value call in the Grahamian sense — earnings and free cash flow are impaired — but a structured income play. If management executes on asset rotations, reduces cash burn, or rebuilds FFO, this stock could compress to a lower yield and higher price. Conversely, sustained FFO weakness would force dividend cuts or a deeper re-rate.
Catalysts (what could move the stock higher)
- Stabilization of FFO through lease renewals or resolution of tenant credit issues, moving reported FFO back toward historical levels.
- Continued dividend increases and consistent payouts that reassure income investors and reduce perceived risk to the dividend.
- Active asset management - accretive acquisitions or disposals that improve portfolio quality and cash flow.
- Technical strength: RSI near 54 and a bullish MACD suggest upside momentum that may attract momentum buyers.
- Any signs of lowering financing costs or refinancing at favorable terms that shrink interest burden and improve FCF.
Trade plan (actionable)
Entry: Buy at $18.30.
Stop loss: $16.00.
Target: $22.00.
Horizon: long term (180 trading days) — roughly 6-9 months. The rationale: dividend income accrues each quarter and operational fixes (lease resolutions, asset rotations, refinancing) play out over multiple quarters. Allowing up to 180 trading days gives time for FFO to recover or for the balance sheet to be managed in ways that materially reduce dividend risk.
Position sizing note: treat this as a higher-risk income sleeve within a diversified portfolio. Because CHCT is relatively small and has negative FCF and above-average leverage, limit the position to an allocation consistent with your risk tolerance (for many retail investors, mid-single-digit percent of equity income exposure rather than broad portfolio allocation).
Risks and counterarguments
- FFO volatility and cash flow pressure: Q2 2025 FFO dropped ~47% (reported 07/30/2025). Ongoing weakness could force a dividend cut despite the company’s track record of quarterly increases.
- Leverage and interest-rate sensitivity: Debt/equity is ~1.33 and enterprise value is roughly double market cap. If financing costs rise or refinancings are pushed to higher rates, interest burden could materially squeeze distributable cash flow.
- Tenant credit and sector risks: Healthcare tenants can experience idiosyncratic credit events (as seen). A concentrated tenant issue or worsening payer/reimbursement environment could intensify losses.
- Negative free cash flow: FCF is -$58.16M, which undermines liquidity and raises questions about the sustainability of outsized dividend yield without asset sales or capital raises.
- Liquidity and small-cap risk: With a float near 26.8M shares and average daily volume around ~202k, large exits or entries can move the stock materially; short interest and recent short-volume readings point to active trading and potential volatility.
Counterargument to the bullish case: An investor could argue that CHCT's high dividend is a red flag rather than an opportunity. The combination of negative free cash flow, elevated leverage and a prior 47% FFO hit make the dividend more likely to be cut if the company hits another tenant-related problem or if capital markets tighten. Those investors would prefer larger, investment-grade healthcare REITs with stronger balance sheets even at lower yields.
What would change my mind
I would downgrade the trade if: (1) management signals a dividend pause or material cut, (2) new tenant credit issues emerge or the company reports another materially negative FFO quarter, or (3) refinancing costs spike such that interest expense materially outpaces cash flow improvements. Conversely, I'll become incrementally more constructive if CHCT posts a couple of consecutive quarters of FFO recovery, reduces negative FCF materially, or executes accretive asset rotations that strengthen the balance sheet.
Conclusion
CHCT is a classic small-cap REIT income trade: attractive headline yield, a reasonable price-to-book, and a path to recovery if FFO stabilizes. That path is neither guaranteed nor short. The trade is for investors who prioritize current income and are comfortable with above-average operational and refinancing risk over the next several quarters. Buy at $18.30 with a $16.00 stop and $22.00 target on a long-term timeline (180 trading days), and keep position sizing conservative while monitoring upcoming earnings and any balance sheet actions closely.